ATE399545T1 - Mittel zur verringerung der eigeweidefette - Google Patents

Mittel zur verringerung der eigeweidefette

Info

Publication number
ATE399545T1
ATE399545T1 AT97911473T AT97911473T ATE399545T1 AT E399545 T1 ATE399545 T1 AT E399545T1 AT 97911473 T AT97911473 T AT 97911473T AT 97911473 T AT97911473 T AT 97911473T AT E399545 T1 ATE399545 T1 AT E399545T1
Authority
AT
Austria
Prior art keywords
agents
egg fat
reducing egg
visceral fat
fat
Prior art date
Application number
AT97911473T
Other languages
English (en)
Inventor
Seiichiro Masui
Yoshihisa Nakano
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Application granted granted Critical
Publication of ATE399545T1 publication Critical patent/ATE399545T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
AT97911473T 1996-11-08 1997-11-07 Mittel zur verringerung der eigeweidefette ATE399545T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP31277096 1996-11-08

Publications (1)

Publication Number Publication Date
ATE399545T1 true ATE399545T1 (de) 2008-07-15

Family

ID=18033213

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97911473T ATE399545T1 (de) 1996-11-08 1997-11-07 Mittel zur verringerung der eigeweidefette

Country Status (5)

Country Link
US (1) US6121288A (de)
EP (1) EP0974348B1 (de)
AT (1) ATE399545T1 (de)
DE (1) DE69738809D1 (de)
WO (1) WO1998020871A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6016327A (en) * 1997-10-03 2000-01-18 At&T Corporation Electronic memory system and method for use in system for reducing quantization noise
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU3455100A (en) * 1999-05-28 2000-12-18 Nippon Chemiphar Co. Ltd. Process for the preparation of 2-halo-3-(3-quinolyl)propionic acid derivatives
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) * 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) * 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
UY26780A1 (es) 2000-06-15 2002-01-31 Pharmacia Corp Cicloalquil avb3 antagonistas
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US20060235061A1 (en) * 2002-06-21 2006-10-19 Qlt,Inc. Methods of using benzothiophenone derivatives to treat cancer or inflammation
US7137203B2 (en) * 2003-12-30 2006-11-21 Eveready Battery Company, Inc. Shaving apparatus
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
NZ711598A (en) 2013-03-14 2016-09-30 Dart Neuroscience Cayman Ltd Substituted naphthyridine and quinoline compounds as mao inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5657775A (en) * 1979-10-17 1981-05-20 Takeda Chem Ind Ltd Thiazole derivative
JPS5759880A (en) * 1980-09-30 1982-04-10 Kyowa Hakko Kogyo Co Ltd Urea derivative and lipometabolism improving agent containing the same
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5646169A (en) * 1987-09-04 1997-07-08 Beecham Group P.L.C. Compounds for treating eating disorders in which blood glucose levels are raised
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
FR2696743B1 (fr) * 1992-10-12 1994-12-23 Adir Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
CA2159938A1 (en) * 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
WO1996012719A1 (en) * 1994-10-20 1996-05-02 Nippon Chemiphar Co., Ltd. Quinoline derivative
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr
JPH09221481A (ja) * 1995-09-22 1997-08-26 Sankyo Co Ltd 芳香族化合物を含有する医薬
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法

Also Published As

Publication number Publication date
DE69738809D1 (de) 2008-08-14
EP0974348B1 (de) 2008-07-02
US6121288A (en) 2000-09-19
WO1998020871A1 (en) 1998-05-22
EP0974348A4 (de) 2003-05-14
EP0974348A1 (de) 2000-01-26

Similar Documents

Publication Publication Date Title
DE69738809D1 (de) Mittel zur verringerung der eigeweidefette
FI950309A0 (fi) Proliiniamidijohdannaisia
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
ATE191477T1 (de) Dihalopropenverbindungen, diese enthaltende insektizide/acarizide mittel und zwischenprodukte zur herstellung davon
GB9801690D0 (en) Therapeutic agents
AU4189596A (en) Benzamidoxime derivatives, method for preparation thereof and fungicide for agricultural and horticultural use
ID24182A (id) Senyawa-senyawa trifluorometilalkilamino-triazolopirimidina untuk fungisida
DE69505490D1 (de) Dihalopropenverbindungen, sie enthaltende insektizide/akarizide mittel, und zwischenprodukte
DK0888289T3 (da) Antikonvulsive, enantiomore aminosyrederivater
IL150965A0 (en) Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
PT1316254E (pt) Composicao de pesticida e metodo para controlar pragas
ATE274903T1 (de) Antivirale mittel
EP0791572A4 (de) Substituierte bicycloheptandione und herbizide
HUT73816A (en) N-arylthiohydrazone derivatives as insecticidal and acaricidal agents
EA199900888A1 (ru) Противоревматические средства
ATE146481T1 (de) Epoxysuccinamidsäurederivat
AU2001228862A1 (en) Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
DE69304011D1 (de) N-Substituierte Carbonyloxyalkylpyrrol enthaltende insekticide, acarizide und molluskizide Mittel
BG105051A (en) Agricultural/horticultural bacterial disease injury-controlling agents
EG20464A (en) Amidothiophosphate derivative and insecticide nematocide acaricide containing the same as active ingredient
WO1999059982A3 (de) Bisoximetherderivate, zwischenprodukte und verwendung zur bekämpfung von schadpilzen und tierischen schädlingen
MX9704976A (es) Derivados de 1,2,3-benzotiadiazol.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties